Ping Zhu, Ph.D., B.M.

Ping Zhu, Ph.D., B.M.

Vice President of Discovery & Research, H3 Biomedicine, Cambridge, MA, USA
 

Dr. Ping Zhu is currently Head of Discovery & Research and an executive leadership team member at H3 Biomedicine, a Cambridge-based, clinical-stage oncology drug discovery company. He has more than 15 years of experience in cancer research and drug discovery. At H3, his group aims to discover next-generation anti-cancer medicines by targeting highly validated molecular targets based upon multiple-dimensional cancer information, e.g. genomics, transcriptomics and functional data, using systematic approaches. Dr. Zhu’s recent research interests include drug targets relevant to lineage, cell state, and immunomodulation; molecular mechanisms of drug resistance; and mechanisms of action of novel small molecules and other drug modalities. At H3, Dr. Zhu and his colleagues have advanced three anti-cancer drug candidates into clinical development and have several additional pipeline programs in discovery.

Dr. Zhu received his Medical Degree (B.M.) from Shanghai Second Medical University in China and a Ph.D. in Molecular Biology from the University of Karlsruhe in Germany. He then finished his postdoctoral training with Michael G. Rosenfeld, M.D. at Howard Hughes Medical Institute and University of California San Diego. Dr. Zhu’s previous work focused on transcriptional and epigenetic regulation in cancer. Prior to joining H3, Dr. Zhu was a group leader at Novartis Institutes for Biomedical Research, where he did significant work with early drug discovery and target identification and validation in oncology, leading multidisciplinary teams across multiple geographic locations. His research has been published in leading scientific journals including Cell, Nature, Cancer Discovery, Cancer Cell and Nature Communications.